Cargando…
Glatiramer acetate does not protect from acute ischemic stroke in mice
BACKGROUND: The role of the immune system in the pathophysiology of acute ischemic stroke is increasingly recognized. However, targeted treatment strategies to modulate immunological pathways in stroke are still lacking. Glatiramer acetate is a multifaceted immunomodulator approved for the treatment...
Autores principales: | Kraft, Peter, Göbel, Kerstin, Meuth, Sven G, Kleinschnitz, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943273/ https://www.ncbi.nlm.nih.gov/pubmed/24576335 http://dx.doi.org/10.1186/2040-7378-6-4 |
Ejemplares similares
-
B cells do not have a major pathophysiologic role in acute ischemic stroke in mice
por: Schuhmann, Michael K., et al.
Publicado: (2017) -
Blocking of platelet glycoprotein receptor Ib reduces “thrombo-inflammation” in mice with acute ischemic stroke
por: Schuhmann, Michael K., et al.
Publicado: (2017) -
COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke
por: Kraft, Peter, et al.
Publicado: (2010) -
Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
por: Mirabella, Massimiliano, et al.
Publicado: (2022) -
Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)